Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated with its now-discontinued heartburn drug Zantac, according to people familiar with the deal.
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle ... which sold Zantac between 1998 and 2006, said it continues to “vigorously defend against Zantac lawsuits, which it ...
opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits ... added. Pfizer did not immediately reply to Reuters' request for comment. First approved in 1983, Zantac ...
London: Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
Pfizer has agreed to pay between $200m to $250m to settle more than 10,000 US lawsuits over cancer risks associated with Zantac, Financial Times reports, citing two unidentified people briefed on the ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...